WO2017146486A1 - Composition for preventing or treating benign prostatic hyperplasia, containing morus alba linne extract - Google Patents

Abstract

The present invention relates to a composition for preventing or treating benign prostatic hyperplasia, containing a Morus alba Linne extract and a Curcumae Rhizoma extract and, specifically, to: a pharmaceutical composition, a food composition and a quasi-drug composition for preventing or treating benign prostatic hyperplasia, all of which contain a Morus alba Linne extract or a fraction thereof and a Curcumae Rhizoma extract or a fraction thereof as active ingredients; and a method for preventing or treating benign prostatic hyperplasia by using the pharmaceutical composition. The composition containing, as an active ingredient, a Morus alba Linne extract, a Curcumae Rhizoma extract or a mixture of a Morus alba Linne extract and a Curcumae Rhizoma extract, of the present invention, has a similar or superior effect of enabling benign prostatic hyperplasia to be prevented, alleviated and treated, in comparison to when performing treatment with finasteride, which is used as a drug for benign prostatic hyperplasia. In addition, the composition of the present invention is derived from a natural product, thereby being safely usable for preventing, treating and alleviating benign prostatic hyperplasia without side effects.

Description

Composition for the prevention or treatment of enlarged prostate, comprising the extract of lettuce

The present invention is Morus alba Linne Extract and Curcumae Rhizoma ) relates to a composition for the prevention or treatment of prostatic hyperplasia comprising an extract, specifically, a pharmaceutical composition, a food composition for preventing or treating prostate hyperplasia comprising an extract of the baekryepi or fractions thereof and an extract of the extract or its fractions as an active ingredient It relates to a quasi-drug composition, and to a method for preventing or treating enlarged prostate using the pharmaceutical composition.

Prostatic hyperplasia is a benign tumor commonly found in middle-aged men in their 40s and 50s. The prostate is enlarged, which causes pressure on the posterior urethra. One of the most common diseases in middle-aged men, usually beginning in their 40s, 50% in their 50s, 60% in their 60s, and 70% in their 70s have prostatic hyperplasia. The number of is gradually increasing proportionally.

To treat such prostate hyperplasia, sympathetic blockers that relieve smooth muscle tone, anti-male hormones that inhibit abnormal proliferation of the prostate epithelium, and 5α-reductase inhibitors are used to improve temporary symptoms. It is used for prevention purposes. However, the sympathetic blocker acts to lower blood pressure, so it is limited to patients with hypotension, and artificially regulates nerves, resulting in bowel movements, resulting in constipation or chronic fatigue. In addition, anti-male hormones can also cause side effects such as decreased libido and erectile dysfunction.

Finasteride is a representative 5α-reductase inhibitor and is commercially available under the trade name Proscar or Propecia. Finasteride inhibits the production of DHT (Dihydrotestosterone), which reduces androgen activity in the scalp, and in the prostate, reduces the weight and volume of the prostate, inhibiting the development of enlarged prostate and reducing the risk of developing prostate cancer (Robaire B et. al., 2006, Molecular and Cellular Endocrinology, 250 (1-2): 190-5.).

Due to the superiority of these effects, development of related technologies using finasteride, such as a novel method for preparing high purity finasteride (Korean Patent No. 0483136), a composition for treating hair loss including polymerized finasteride nanoparticles (Korea Patent Publication No. 2015-0046332), etc. It is done. However, side effects that increase the incidence of breast cancer in men and cause sexual dysfunction have been reported and require caution (Medicines and Healthcare products Regulatory Agency Drug Safety Update, 2009; Mella JM et al., 2010), Archives of Dermatology 146 (10): 1141-50.).

On the other hand, Morus alba Linne) is a medicinal herb made from the mulberry of the mulberry family or from the roots of the same plant. It has been proven to be effective in treating atherosclerosis and essential hypertension. In addition, it has been known that the extract may be used for the treatment of depression (Korean Patent Publication No. 2009-0116547), the effect on the enlarged prostate has not been found.

The present inventors have completed the present invention by confirming that the composition containing the extract of the lettuce extract, which is a natural herb, has an excellent effect on prostate hyperplasia, as a result of earnest research efforts to develop a prostate hypertrophy having no side effects and excellent efficacy.

One object of the present invention is Morus It is to provide a pharmaceutical composition for the prevention or treatment of enlarged prostate, comprising alba Linne) extract or a fraction thereof as an active ingredient.

Another object of the present invention is to provide a method for preventing or treating prostatic hyperplasia comprising administering the pharmaceutical composition to a subject.

Still another object of the present invention is to provide a food composition for preventing or improving prostate hyperplasia comprising an extract of E. coli or a fraction thereof as an active ingredient.

Still another object of the present invention is to provide a quasi-drug composition for preventing or ameliorating prostate hyperplasia comprising an extract of E. coli or a fraction thereof as an active ingredient.

The composition comprising the extract of the extract from the extract of the present invention, the extract from the extract, or the mixture of the extract from the extract from the extract, and the extract from the extract, the prostate hypertrophy is similar to or better than that treated with finasteride, which is used as an agent for prostatic hyperplasia. It is effective to prevent, improve and treat.

In addition, since the composition of the present invention is derived from natural products, it can be safely used without side effects in the prevention, treatment and improvement of prostate hyperplasia.

1 is a graph showing the prostate weight reduction effect of each extract according to the present invention. NC means normal control group and BPH means prostatic hyperplasia control group, Finasteride treatment group was used as a positive control. All values are expressed as mean ± SEM. The statistical significance of each result was confirmed by ANOVA test, and different subscripts represented by a, b, c or d mean significant difference at p <0.01.

One aspect of the present invention for achieving the above object is Morus alba Linne) provides a pharmaceutical composition for the prevention or treatment of enlarged prostate, comprising an extract or a fraction thereof as an active ingredient.

Also, the present invention is Morus alba Linne) extract or a fraction thereof as an active ingredient provides a prophylactic or therapeutic use of prostatic hyperplasia.

In the present invention, in addition to the extract of the extract, the mixture of the extract of Achul extract in the extract of the lettuce extract effectively reduces the prostate weight of the experimental animal inducing prostatic hyperplasia, so that the extract or mixture of extracts of the therapeutic agent of prostatic hyperplasia It was confirmed that it can be used as an active ingredient.

The term of the present invention, " Morus " alba Linne) "means a medicinal herb made from the mulberry of the Mulberry family or from the roots of the same plant. Generally, the roots are peeled, peeled and sunk until they germinate until late spring and next spring germination. Although it has been known that it has some peculiar smell and little taste, the epidermis is known to be effective for chest pain caused by chronic bronchitis, coronary atherosclerosis, etc., but the therapeutic effect of prostate-related diseases is not known, and it is known to the present inventors. Was first identified.

The lettuce skin may be purchased commercially, or may be used collected or grown in nature.

The term "extract" of the present invention refers to extracts themselves, such as extracts obtained by extracting the baekbaekpi, dilutions or concentrates of the extracts, dried products obtained by drying the extracts, crude or purified products of the extracts, or mixtures thereof. And extracts of all formulations that can be formed using extracts.

The method of extracting the baekbaekpi is not particularly limited, and may be extracted according to a method commonly used in the art. Non-limiting examples of the extraction method, hot water extraction method, ultrasonic extraction method, filtration method, reflux extraction method, and the like, these may be performed alone or in combination of two or more methods.

In the present invention, the type of extraction solvent used to extract the baekryepi is not particularly limited, and any solvent known in the art may be used. Non-limiting examples of the extraction solvent may include water, alcohols having 1 to 4 carbon atoms or mixed solvents thereof, and these may be used alone or in combination of one or more thereof. Specific 70% ethanol may be used, but is not limited thereto.

As used herein, the term "fraction" refers to the result obtained by performing fractionation to separate a specific component or a specific group of components from a mixture comprising several various components.

The fractionation method of obtaining the fraction in the present invention is not particularly limited, and may be performed according to a method commonly used in the art. As a non-limiting example of the fractionation method, a method of obtaining a fraction from the extract by treating a predetermined solvent with an extract obtained by extracting the baekryepi of the present invention.

The kind of the fractionation solvent used to obtain the fraction in the present invention is not particularly limited, and any solvent known in the art may be used. Non-limiting examples of the fractionation solvents include polar solvents such as water and alcohols having 1 to 4 carbon atoms; Nonpolar solvents such as hexane, ethyl acetate, chloroform and dichloromethane; Or a mixed solvent thereof. These may be used alone or in combination of one or more, but are not limited thereto.

In addition, the extract or fraction may be prepared and used in the form of a dry powder after extraction, but is not limited thereto.

The term "prostate hyperplasia" of the present invention refers to a disease in which the prostate enlarges abnormally and makes urinary tract difficult to urinate, and the prostate is enlarged and diagnosed as prostatic hyperplasia when accompanied by lower urinary tract symptoms. Prostate hyperplasia is one of the most common diseases occurring in middle-aged men. It is known that 50%, 60% in 60s, and 70% in 70s usually start in their 40s.

The pharmaceutical composition for preventing or treating prostatic hyperplasia of the present invention may further include ahyeol extract or a fraction thereof as an active ingredient.

The term “ curcumae Rhizoma ” refers to a medicinal herb prepared by drying the rhizome of Curcuma zedoaria , Curcuma phaeocaulis Val., Curcuma kwangsiensis SG Lee et CF Liang, or Curcuma wenyujin YH Chen et C. Ling. It is 2 ~ 8cm long and 1.5 ~ 4cm in diameter and has an outer shape of oval, long round, conical or long fusiform. It has a slightly peculiar smell and the taste is known to be bitter and spicy. Although effects on amenorrhea, menstrual cramps, indigestion, bruises and the like are known, the therapeutic effect of prostate-related diseases is not known and was first identified by the present inventors.

The outbreak may be purchased commercially, or may be used collected or grown in nature.

As used herein, the term "prevention" refers to all acts that inhibit or retard prostatic hyperplasia by administration of the pharmaceutical composition of the present invention, which includes an extract of the baekryepi or fractions thereof, and further comprising an extract or fractions thereof. it means.

As used herein, the term "treatment" means any action in which an enlarged or beneficially improved prostate enlargement is administered by administration of the pharmaceutical composition.

In a specific embodiment of the present invention, when the experimental animal was treated with an extract of the lettuce extract, acupuncture extract, or a mixture of the extract of lettuce and extracts, it was confirmed that the weight of the prostate of the experimental animal induced by the enlarged prostate was reduced (Table 1). And FIG. 1). This suggests that the extract or a mixture of extracts of the present invention can be used as an active ingredient in the treatment of enlarged prostate.

The pharmaceutical composition of the present invention may include 0.0001 to 50% by weight of the baekryepi extract relative to the weight of the total composition, specifically may include 0.01 to 10% by weight, but is not limited thereto.

In addition, the extract may be included in 0.0001 to 50% by weight, specifically may include 0.01 to 10% by weight, but is not limited thereto.

The pharmaceutical composition of the present invention may include the extract of baekryepi and Achul extract in a weight ratio of 0.001 to 5: 0.001 to 5, specifically may be included in a weight ratio of 0.001 to 3: 0.001 to 3, more specifically 1: It may include a weight ratio of 1, but is not limited thereto.

The pharmaceutical composition of the present invention may include a mixture of lettuce extract alone or amalgam extract, and may also include an extract of a mixture of lettuce extract and amalgam, and may specifically include a mixture of lettuce extract alone or amalgam extract. This is not restrictive.

The pharmaceutical composition of the present invention may further comprise a pharmaceutically acceptable carrier, excipient or diluent commonly used in the manufacture of the pharmaceutical composition, which carrier may comprise a non-naturally occuring carrier. have.

The pharmaceutical compositions may be used in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols and the like, oral formulations, external preparations, suppositories, and sterile injectable solutions, respectively, according to a conventional method.

As used herein, the term "pharmaceutically acceptable" means to exhibit properties that are not toxic to cells or humans exposed to the composition.

Specifically, the type of the carrier is not particularly limited, and any carrier can be used as long as it is a conventionally used and pharmaceutically acceptable carrier in the art. Non-limiting examples of the carrier include saline, sterile water, Ringer's solution, buffered saline, albumin injection solution, dextrose solution, maltodextrin solution, glycerol, ethanol and the like. These may be used alone or in combination of two or more thereof. In addition, if necessary, other conventional additives such as antioxidants, buffers and / or bacteriostatic agents may be added and used, and diluents, dispersants, surfactants, binders, lubricants, and the like may be additionally added to provide a solution such as an aqueous solution, a suspension, an emulsion, or the like. It may be formulated into a use formulation, pills, capsules, granules or tablets.

The mode of administration of the pharmaceutical composition for preventing or treating prostatic hyperplasia according to the present invention is not particularly limited, and may be in accordance with a conventional method used in the art. As a non-limiting example of the mode of administration, the composition may be administered by oral or parenteral administration. In addition, the composition for preventing, ameliorating or treating the enlarged prostate of the present invention may be prepared in various formulations according to the desired administration mode.

Another aspect provides a method of preventing or treating enlarged prostate, comprising administering the pharmaceutical composition to a subject.

In this case, the definition of the enlarged prostate, prevention and treatment is as described above.

As used herein, the term "administration" means the introduction of certain substances into an individual in a suitable manner.

As used herein, the term "individual" means all animals, such as rats, mice, and livestock, including humans that may develop or may develop prostatic hyperplasia. As a specific example, it may be a mammal including a human.

Specifically, the method for preventing or treating prostatic hyperplasia of the present invention comprises the step of administering a pharmaceutical composition comprising a lettuce extract or a fraction thereof, and further comprising a subcutaneous extract or a fraction thereof in a pharmaceutically effective amount to the individual. can do.

As used herein, the term “pharmaceutically effective amount” means an amount sufficient to treat the disease at a reasonable benefit / risk ratio applicable to medical treatment and that does not cause side effects, and the effective dose level refers to the sex, Factors including age, weight, health, type of disease, severity, drug activity, drug sensitivity, method of administration, time of administration, route of administration, and rate of excretion, duration of treatment, combination or drug used and other medicines It can be easily determined by those skilled in the art according to factors well known in the art.

The composition of the present invention may be administered in 0.0001 to 100 mg / kg body weight per day, more specifically 0.001 to 100 mg / kg body weight based on solids. Dosing may include administering the recommended dose once daily, or in divided doses.

In the method for preventing or treating prostatic hyperplasia of the present invention, the route of administration and mode of administration of the composition are not particularly limited, and any route of administration can be reached as long as the composition comprising the composition can be reached at the desired site. Depending on the mode of administration. Specifically, the composition may be administered through various routes, oral or parenteral, and non-limiting examples of the route of administration include oral, rectal, topical, intravenous, intraperitoneal, intramuscular, intraarterial, transdermal, nasal What is administered through intralateral or inhalation etc. are mentioned.

Another embodiment provides a food composition for preventing or improving prostate hyperplasia comprising an extract of E. coli or a fraction thereof as an active ingredient.

At this time, the definition of the epidermis, extract, fraction, prostatic hyperplasia and prevention is as described above.

Food composition for preventing or improving the prostate hypertrophy of the present invention comprises an extract of the baekryepi or fractions thereof, and may further comprise ahyeol extract or fractions thereof as an active ingredient.

As used herein, the term " improvement " means any action that at least reduces the parameters associated with the condition to be treated with the administration of the compositions of the present invention, eg the extent of symptoms.

The term "food" of the present invention, meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gum, dairy products including ice cream, various soups, drinks, tea, drinks, alcoholic beverages , Vitamin complexes, nutraceuticals and health foods, and includes all foods in the usual sense.

Since the food composition of the present invention can be consumed on a daily basis, a high prostate hypertrophy improvement effect can be expected, and thus can be very useful for health promotion purposes.

The functional food (functional food) is the same term as a food for special health use (Food for special health use, FoSHU), in addition to the nutritional supply, the processed food, so that the bioregulatory function appears efficiently, high medical effect Means food. Here, the term 'function (sex)' refers to obtaining a useful effect for health purposes such as nutrient control or physiological action on the structure and function of the human body. The food of the present invention may be prepared by a method commonly used in the art, and the preparation may be performed by adding raw materials and ingredients commonly added in the art. In addition, the formulation of the food may be prepared without limitation as long as the formulation is recognized as a food. Food composition of the present invention can be prepared in a variety of formulations, unlike the general drug has the advantage that there is no side effect that may occur when taking a long-term use of the drug as a food raw material, because the portability is excellent, The food of the present invention can be taken as an adjuvant for enhancing the effect of improving the prostate enlargement.

The health food refers to foods having active health maintenance or promotion effect as compared to general foods, and the health supplement food refers to foods for health supplementation purposes. In some cases, the terms nutraceutical, health food, dietary supplement are used.

Specifically, the health functional food is a food prepared by adding the compound of the present invention to food materials such as beverages, teas, spices, gums, confections, or the like, encapsulated, powdered, suspensions, etc. Means to bring effect, but unlike the general medicine has the advantage that there is no side effect that can occur when taking long-term use of the drug as a raw material.

The food composition may further include a physiologically acceptable carrier, and the type of carrier is not particularly limited and may be any carrier that is commonly used in the art.

In addition, the food composition may include additional ingredients that are commonly used in food compositions to improve the smell, taste, time and the like. For example, it may include vitamins A, C, D, E, B1, B2, B6, B12, niacin, biotin, folate, panthotenic acid, and the like. In addition, minerals such as zinc (Zn), iron (Fe), calcium (Ca), chromium (Cr), magnesium (Mg), manganese (Mn), copper (Cu) and chromium (Cr); And amino acids such as lysine, tryptophan, cysteine, valine and the like.

In addition, the food composition is a preservative (potassium sorbate, sodium benzoate, salicylic acid, sodium dehydroacetic acid, etc.), fungicides (bleaching powder and highly bleaching powder, sodium hypochlorite, etc.), antioxidants (butylhydroxyanisol (BHA), butylhydride) Oxytoluene (BHT), etc.), colorant (such as tar pigment), colorant (sodium nitrite, sodium nitrite, etc.), bleach (sodium sulfite), seasoning (MSG glutamate, etc.), sweetener (ducin, cyclate, saccharin Foods such as sodium, etc.), fragrances (vanillin, lactones, etc.), swelling agents (alum, potassium D-tartrate, etc.), reinforcing agents, emulsifiers, thickeners (foils), coatings, gum herbicides, foam inhibitors, solvents, modifiers It may include food additives. The additive may be selected according to the type of food and used in an appropriate amount.

An example of the food composition of the present invention may be used as a health beverage composition, in which case it may contain various flavors or natural carbohydrates and the like as additional ingredients, such as a general beverage. The above-mentioned natural carbohydrates include monosaccharides such as glucose and fructose; Disaccharides such as maltose and sucrose; Polysaccharides such as dextrin, cyclodextrin; Sugar alcohols such as xylitol, sorbitol, and erythritol. Sweeteners include natural sweeteners such as taumartin, stevia extract; Synthetic sweeteners such as saccharin and aspartame; The ratio of the natural carbohydrate may generally be about 0.01 to 0.04 g, specifically about 0.02 to 0.03 g, per 100 mL of the health beverage composition of the present invention.

In addition to the above, the health beverage composition includes various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid, salts of pectic acid, alginic acid, salts of alginic acid, organic acids, protective colloid thickeners, pH regulators, stabilizers, preservatives, glycerin, Alcohol or carbonation agent and the like. Others may contain fruit flesh for the production of natural fruit juices, fruit juice drinks, or vegetable drinks. These components can be used independently or in combination. Although the ratio of such an additive is not critical, it is generally selected from the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the health beverage composition of the present invention.

Another embodiment provides a quasi-drug composition for the prevention or improvement of prostate hyperplasia comprising an extract of the epidermis or a fraction thereof as an active ingredient.

At this time, the definition of the epidermis, extract, fraction, prostatic hyperplasia, prevention and improvement are as described above.

The quasi-drug composition for preventing or improving the prostate hypertrophy of the present invention may include an extract of the lettuce extract or a fraction thereof, and may further include an extract or an extract thereof as an active ingredient.

As used herein, the term "quasi drug" refers to a fiber, rubber product or the like used for the purpose of treating, alleviating, treating or preventing a disease of a human or animal, and has a weak action on the human body or does not directly act on the human body. Or non-machinery and the like, or any of the agents used for sterilization, insecticide and similar uses for the purpose of preventing infection, for the purpose of diagnosing, treating, alleviating, treating or preventing human or animal diseases. It may mean an article other than an apparatus, machine or apparatus, and an article which is not an apparatus, machine or apparatus, which is used for the purpose of pharmacologically affecting the structure and function of a human or animal. In addition, the quasi-drug may include external skin preparations and personal hygiene products.

When the extract according to the present invention or a fraction thereof is used as an quasi-drug additive, the extract or a fraction thereof may be added as it is, or used together with other quasi-drug or quasi-drug components, and may be appropriately used according to a conventional method. The mixing amount of the active ingredient may be appropriately determined depending on the intended use.

The external preparation for the skin is not particularly limited thereto, but may be prepared and used, for example, in the form of an ointment, lotion, spray, patch, cream, powder, suspension, gel or gel.

The quasi-drug composition of the present invention may be included in various weight% if it can exhibit the effect of preventing or improving prostate hyperplasia, but specifically the extract or fractions of the present invention 0.01 to 100% by weight, more specifically, the total weight of the quasi-drug composition It may include 1 to 80% by weight.

Hereinafter, the present invention will be described in more detail with reference to the following examples. However, the following examples are only for illustrating the present invention, and the scope of the present invention is not limited thereto.

Preparation Example 1 Preparation of Extract

Preparation Example 1-1. Preparation of Morus Extract

Sangbaekpi (Scientific name: Morus alba Linne, herbal name: Mori Radicis Cortex) extract was prepared by the following method. After commercially available commercial white skin was pulverized, 10 L of 70% ethanol was added to 1 kg of ground matter. Thereafter, ultrasonic extraction was performed three times for 1 hour. The ultrasonic extract was filtered through an Advantec No. 2 (110 mm) filter paper to remove insoluble matters, and then concentrated under reduced pressure at 45 ° C. with a condenser equipped with a cooling condenser. In order to completely remove the solvent of the extract concentrated under reduced pressure, 500 mL of purified water was added and suspended, and 146.4 g of an extract was obtained using a lyophilizer (yield 14.6%).

Preparation Example 1-2. Preparation of Achul Extract

Curcumae Rhizoma extract was prepared by the following method. Commercially available extracts were obtained and ground, and then 10 L of 70% ethanol was added to 1 kg of the ground product. Thereafter, ultrasonic extraction was performed three times for 1 hour. The ultrasonic extract was filtered through an Advantec No. 2 (110 mm) filter paper to remove insoluble matters, and then concentrated under reduced pressure at 45 ° C. with a condenser equipped with a cooling condenser. In order to completely remove the solvent of the extract concentrated under reduced pressure, 500 mL of purified water was added and suspended, and then 41.43 g of an extract was obtained using a lyophilizer (yield 4.14%).

Example 1 Analysis of Effects of Extract on Prostatic Hyperplasia

Example 1-1. Measurement of prostate weight

Since the increase in the weight of the prostate gland is one of the main symptoms of prostatic hyperplasia, the following experiments were performed to analyze the effect of each extract on prostatic hyperplasia.

200 to 220 g of male SD rats (Sprague-Dawley rats, Orient Bio) were purified for 1 week, and then used in the experiment as 6 of each group.

A prostatic hypertrophy-induced control group was prepared by injecting 10 mg / kg TP (testosterone propionate) subcutaneously for 4 weeks.

The experimental group treated with each extract was prepared by orally administering the extract of the lettuce extract, Achul extract or a mixture of lettuce extract and Achul (1: 1) prepared at Example 1 one hour before TP injection at 100 mg / kg for 4 weeks. . The mixture was prepared by mixing the extracted epidermis and buds in a solvent immediately before administration.

A positive control group treated with finasteride, a 5α-reductase inhibitor used as a prostatic hypertrophy drug, was prepared by orally administering finasteride at 10 mg / kg.

In the normal control, corn oil was injected subcutaneously.

Then, the prostate weight of the experimental animal according to the treatment of each extract is summarized in Table 1 below.

Relative prostate weight Mean SD SEM P-value NC (normal control) 0.0021 0.0003 0.0001 BPH (prostatic hypertrophy control) 0.0057 0.0007 0.0003 P <0.01 Finasteride 0.0045 0.0003 0.0001 P <0.01 ①White Skin 0.0044 0.0004 0.0002 P <0.01 ② Outing 0.0048 0.0005 0.0002 P <0.01 ③ Whitening Skin + Morning 0.0037 0.0004 0.0002 P <0.01

As a result, as can be seen in Table 1 and Figure 1, when the experimental animal treated with a mixture of lettuce extract, Achul extract, or a mixture of lettuce extract and Achul extract, its weight is greater than the weight of the prostate of the experimental animal induced prostatic hyperplasia It was confirmed that the decrease. In addition, it was confirmed that this effect is similar to or better than the case of the treatment with finasteride (Finasteride) used as a drug of prostatic hyperplasia.

In addition, it was confirmed that the mixture of the extracts of the extracts of the extracts of the extract and the extracts of the prostate was more effective in reducing the weight of the prostate than the treatment of the extracts of the extracts or extracts.

Through the above results, it can be seen that the extract or the mixture of the present invention can be effectively used for the treatment of enlarged prostate.

From the above description, those skilled in the art will appreciate that the present invention can be implemented in other specific forms without changing the technical spirit or essential features. In this regard, the embodiments described above are to be understood in all respects as illustrative and not restrictive. The scope of the present invention should be construed that all changes or modifications derived from the meaning and scope of the following claims and equivalent concepts rather than the detailed description are included in the scope of the present invention.

Claims (10)

A pharmaceutical composition for preventing or treating enlarged prostate, comprising Morus alba Linne extract or fractions thereof and Curcumae Rhizoma extract or fractions thereof as an active ingredient. The pharmaceutical composition according to claim 1, wherein the extract of Morus alba or extract is extracted with a solvent selected from the group consisting of water, alcohols having 1 to 4 carbon atoms, and mixed solvents thereof. The method of claim 1, wherein the fraction consists of water extract, alcohol having 1 to 4 carbon atoms, hexane (Hexan), ethyl acetate (Ethyl acetate), chloroform (Chloroform), dichloromethane (dichloromethane) and a mixed solvent thereof It is prepared by fractionation with a solvent selected from the group consisting of, pharmaceutical compositions. According to claim 1, wherein the fraction is Achul extract consisting of water, alcohol having 1 to 4 carbon atoms, hexane (Hexan), ethyl acetate (Ethyl acetate), chloroform (Chloroform), dichloromethane (dichloromethane) and a mixed solvent thereof It is prepared by fractionation with a solvent selected from the group consisting of, pharmaceutical compositions. The pharmaceutical composition of claim 1, wherein the lettuce extract or azu extract is prepared by extraction by ultrasonic extraction. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition comprises an extract of Morus alba L. or Achul extract in an amount of 0.0001 to 50% by weight based on the total weight of the composition. The composition of claim 1, wherein the pharmaceutical composition comprises an extract of lettuce and extracts in a weight ratio of 0.001 to 3: 0.001 to 3. A method for preventing or treating enlarged prostate, comprising administering to a subject a pharmaceutical composition according to any one of claims 1 to 7. Morus alba Linne extract or fractions thereof and curcumae Rhizoma extracts or fractions thereof as an active ingredient for preventing or improving prostate hypertrophy food composition. A quasi-drug composition for preventing or improving enlarged prostate, comprising Morus alba Linne extract or fractions thereof and Curcumae Rhizoma extract or fractions thereof as an active ingredient.

Images